LifeVantage Corporation announced its financial results for the second fiscal quarter, ending December 31, 2025. Revenue during this period was $48.9 million, up 2.9% sequentially, but down 27.8% year-over-year. Revenue in the Americas fells by 32.6% while revenue in Asia/Pacific and Europe saw relative stability with a 2.1% decline.
The company attributed revenue challenges primarily to declines in sales of the MindBody GLP-1 System, but stated that its acquisition of LoveBiome and the LoveBiome product line helped offset this decline. Gross profit during the period was $36.2 million, or 74% of revenue, down from $54.6 million and 80.5% of revenue in the prior year’s period.
Adjusted EBITDA was $3.9 million, compared to $6.5 million in the prior year’s period, while operating income was $0.5 million, compared to $3.4 million last year.
“The second quarter reflected challenging competitive dynamics in the weight loss market as we cycled the launch of our MindBody GLP-1 System in October 2024,” said Steve Fife, LifeVantage President and CEO. “We acknowledge that our performance during the quarter did not meet your expectations or ours and we are redoubling our efforts to stabilize our GLP-1 business and make the other changes necessary to return to revenue growth. While the growth trajectory of MindBody may have changed, we remain committed to this proven, scientifically validated natural weight loss solution. We continue to be very well positioned across the broader health and wellness ecosystem and are particularly excited about the momentum we are seeing in LoveBiome, including several new products launching over the next couple quarters that will expand the portfolio into adjacent, high-growth categories. This summer and beyond, LifeVantage also plans to expand into new international markets, another key element of our overall growth strategy. With a strong balance and proven track record of returning capital to shareholders, we remain steadfast in our commitment to driving long-term shareholder value.”
The company ended the period with cash and cash equivalents of $10.2 million, down from $20.2 million in the previous quarter, with no outstanding debt.
The post LifeVantage Reports Fiscal Q2 2025 Financial Results first appeared on Direct Selling News.
